239 related articles for article (PubMed ID: 24777841)
1. Vision-related quality of life and visual function following intravitreal bevacizumab injection for persistent diabetic macular edema after vitrectomy.
Okamoto Y; Okamoto F; Hiraoka T; Oshika T
Jpn J Ophthalmol; 2014 Jul; 58(4):369-74. PubMed ID: 24777841
[TBL] [Abstract][Full Text] [Related]
2. Vision-Related Quality of Life in Patients with Diabetic Macular Edema Treated with Intravitreal Aflibercept: The AQUA Study.
Garweg JG; Stefanickova J; Hoyng C; Schmelter T; Niesen T; Sowade O; Sivaprasad S;
Ophthalmol Retina; 2019 Jul; 3(7):567-575. PubMed ID: 31080168
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
4. Vision-related quality of life after pars plana vitrectomy with or without combined cataract surgery for idiopathic macular hole patients.
Wang Y; Liang X; Gao M; Liu J; Liu L; Liu W
Int Ophthalmol; 2019 Dec; 39(12):2775-2783. PubMed ID: 31144239
[TBL] [Abstract][Full Text] [Related]
5. Repeated intravitreal bevacizumab injection with and without macular grid photocoagulation for treatment of diffuse diabetic macular edema.
Solaiman KA; Diab MM; Dabour SA
Retina; 2013 Sep; 33(8):1623-9. PubMed ID: 23538584
[TBL] [Abstract][Full Text] [Related]
6. Effect of intravitreal bevacizumab based on optical coherence tomography patterns of diabetic macular edema.
Kim M; Lee P; Kim Y; Yu SY; Kwak HW
Ophthalmologica; 2011; 226(3):138-44. PubMed ID: 21822008
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of intravitreal anti-vascular endothelial growth factor or steroid injection in diabetic macular edema according to fluid turbidity in optical coherence tomography.
Lee K; Chung H; Park Y; Sohn J
Korean J Ophthalmol; 2014 Aug; 28(4):298-305. PubMed ID: 25120338
[TBL] [Abstract][Full Text] [Related]
8. Paired responses to intravitreal bevacizumab in diabetic macular edema: predictors of response in the fellow eye.
Karth PA; Chang A; Wirostko W
Graefes Arch Clin Exp Ophthalmol; 2014 Feb; 252(2):207-11. PubMed ID: 23873254
[TBL] [Abstract][Full Text] [Related]
9. Vision-related quality of life and visual function after vitrectomy for various vitreoretinal disorders.
Okamoto F; Okamoto Y; Fukuda S; Hiraoka T; Oshika T
Invest Ophthalmol Vis Sci; 2010 Feb; 51(2):744-51. PubMed ID: 19815727
[TBL] [Abstract][Full Text] [Related]
10. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
11. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months.
Arevalo JF; Sanchez JG; Wu L; Maia M; Alezzandrini AA; Brito M; Bonafonte S; Lujan S; Diaz-Llopis M; Restrepo N; RodrÃguez FJ; Udaondo-Mirete P;
Ophthalmology; 2009 Aug; 116(8):1488-97, 1497.e1. PubMed ID: 19545900
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab for treatment of diabetic macular edema.
Seo JW; Park IW
Korean J Ophthalmol; 2009 Mar; 23(1):17-22. PubMed ID: 19337474
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema.
Soheilian M; Ramezani A; Bijanzadeh B; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Tabatabaei H; Peyman GA
Retina; 2007; 27(9):1187-95. PubMed ID: 18046223
[TBL] [Abstract][Full Text] [Related]
14. Optical coherence tomographic patterns in diabetic macula edema can predict the effects of intravitreal bevacizumab injection as primary treatment.
Wu PC; Lai CH; Chen CL; Kuo CN
J Ocul Pharmacol Ther; 2012 Feb; 28(1):59-64. PubMed ID: 21992557
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab (Avastin) versus triamcinolone (Volon A) for treatment of diabetic macular edema: one-year results.
Kriechbaum K; Prager S; Mylonas G; Scholda C; Rainer G; Funk M; Kundi M; Schmidt-Erfurth U;
Eye (Lond); 2014 Jan; 28(1):9-15; quiz 16. PubMed ID: 24336297
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema.
Solaiman KA; Diab MM; Abo-Elenin M
Retina; 2010; 30(10):1638-45. PubMed ID: 20838357
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema.
Soheilian M; Ramezani A; Obudi A; Bijanzadeh B; Salehipour M; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Peyman GA
Ophthalmology; 2009 Jun; 116(6):1142-50. PubMed ID: 19376585
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular edema: results of the Pan-american Collaborative Retina Study Group at 24 months.
Arevalo JF; Lasave AF; Wu L; Diaz-Llopis M; Gallego-Pinazo R; Alezzandrini AA; Berrocal MH;
Retina; 2013 Feb; 33(2):403-13. PubMed ID: 23222389
[TBL] [Abstract][Full Text] [Related]
19. Visual outcome after intravitreal bevacizumab depends on the optical coherence tomographic patterns of patients with diffuse diabetic macular edema.
Shimura M; Yasuda K; Yasuda M; Nakazawa T
Retina; 2013 Apr; 33(4):740-7. PubMed ID: 23222391
[TBL] [Abstract][Full Text] [Related]
20. Comparison of intravitreal triamcinolone acetonide versus intravitreal bevacizumab as the primary treatment of clinically significant macular edema.
Liu Q; Hu Y; Yu H; Yuan L; Hu J; Atik A; Guan M; Li D; Li X; Tang S
Retina; 2015 Feb; 35(2):272-9. PubMed ID: 25105313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
